Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1976 1
1978 1
1983 1
1984 1
1985 2
1986 1
1988 1
1989 1
1990 2
1991 1
1992 4
1993 4
1994 2
1995 3
1996 2
1997 2
1998 2
1999 3
2000 2
2001 6
2002 5
2003 1
2004 4
2005 2
2006 5
2007 8
2008 5
2009 3
2010 8
2011 12
2012 7
2013 5
2014 8
2015 6
2016 3
2017 4
2018 8
2019 8
2020 3
2021 6
2022 11
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

151 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Recurrent Bladder Squamous Cell Carcinoma"
Page 1
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma.
Powles T, Assaf ZJ, Davarpanah N, Banchereau R, Szabados BE, Yuen KC, Grivas P, Hussain M, Oudard S, Gschwend JE, Albers P, Castellano D, Nishiyama H, Daneshmand S, Sharma S, Zimmermann BG, Sethi H, Aleshin A, Perdicchio M, Zhang J, Shames DS, Degaonkar V, Shen X, Carter C, Bais C, Bellmunt J, Mariathasan S. Powles T, et al. Nature. 2021 Jul;595(7867):432-437. doi: 10.1038/s41586-021-03642-9. Epub 2021 Jun 16. Nature. 2021. PMID: 34135506 Clinical Trial.
The rate of ctDNA clearance at week 6 was higher in the atezolizumab arm (18%) than in the observation arm (4%) (P = 0.0204). Transcriptomic analysis of tumours from patients who were positive for ctDNA revealed higher expression levels of cell-cycle and keratin gen …
The rate of ctDNA clearance at week 6 was higher in the atezolizumab arm (18%) than in the observation arm (4%) (P = 0.0204). Transcr …
Neoadjuvant Pembrolizumab and Radical Cystectomy in Patients with Muscle-Invasive Urothelial Bladder Cancer: 3-Year Median Follow-Up Update of PURE-01 Trial.
Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, Briganti A, Montorsi F, Necchi A. Basile G, et al. Clin Cancer Res. 2022 Dec 1;28(23):5107-5114. doi: 10.1158/1078-0432.CCR-22-2158. Clin Cancer Res. 2022. PMID: 36190522 Clinical Trial.
PURPOSE: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) in patients with muscle-invasive urothelial bladder carcinoma (MIBC). We herein present the survival outcomes after a median f …
PURPOSE: The PURE-01 study (NCT02736266) pioneered the neoadjuvant immune-checkpoint inhibitor (ICI) therapy before radical cystectomy (RC) …
Circulating Tumor DNA Analysis in Advanced Urothelial Carcinoma: Insights from Biological Analysis and Extended Clinical Follow-up.
Lindskrog SV, Birkenkamp-Demtröder K, Nordentoft I, Laliotis G, Lamy P, Christensen E, Renner D, Andreasen TG, Lange N, Sharma S, ElNaggar AC, Liu MC, Sethi H, Aleshin A, Agerbæk M, Jensen JB, Dyrskjøt L. Lindskrog SV, et al. Clin Cancer Res. 2023 Dec 1;29(23):4797-4807. doi: 10.1158/1078-0432.CCR-23-1860. Clin Cancer Res. 2023. PMID: 37782315 Free PMC article.
No statistically significant difference in recurrence-free survival for patients without detectable ctDNA at diagnosis was observed between the cohorts. Baseline ctDNA positivity was associated with the Basal/Squamous (Ba/Sq) subtype and enrichment of epithel …
No statistically significant difference in recurrence-free survival for patients without detectable ctDNA at diagnosis was observe …
Metastasis and recurrence patterns in the molecular subtypes of urothelial bladder cancer.
Sjödahl G, Eriksson P, Holmsten K, Abrahamsson J, Höglund M, Bernardo C, Ullén A, Liedberg F. Sjödahl G, et al. Int J Cancer. 2024 Jan 1;154(1):180-190. doi: 10.1002/ijc.34715. Epub 2023 Sep 6. Int J Cancer. 2024. PMID: 37671617
Urothelial cancer of the urinary bladder frequently metastasizes to lymph-nodes, lungs, liver and bone. ...We observed significant depletion of bone metastases in the Basal/squamous molecular subtype, whereas the Urothelial-like subtype entailed an enr …
Urothelial cancer of the urinary bladder frequently metastasizes to lymph-nodes, lungs, liver and bone. ...We observed …
miRNA and cancer; computational and experimental approaches.
Tutar Y. Tutar Y. Curr Pharm Biotechnol. 2014;15(5):429. doi: 10.2174/138920101505140828161335. Curr Pharm Biotechnol. 2014. PMID: 25189575
The rest of the issue highlights the roles of miRNAs on multiple myeloma, non-small cell lung cancer, urological malignancies, myeloid leukemia, and laryngeal squamous cell carcinoma. ...Laryngeal squamous cell carcinoma is the lar …
The rest of the issue highlights the roles of miRNAs on multiple myeloma, non-small cell lung cancer, urological malignancies, myeloi …
Clinical Significance of Squamous Differentiation in Urothelial Carcinoma of the Bladder.
Minato A, Noguchi H, Tomisaki I, Fukuda A, Kubo T, Nakayama T, Fujimoto N. Minato A, et al. Cancer Control. 2018 Jan-Dec;25(1):1073274818800269. doi: 10.1177/1073274818800269. Cancer Control. 2018. PMID: 30213195 Free PMC article.
The prognostic value of squamous differentiation (SD) in urothelial carcinoma (UC) of the bladder is unclear. ...Our results indicate that SD may be an independent predictor of OS and RFS in UC of MIBC in patients undergoing RC....
The prognostic value of squamous differentiation (SD) in urothelial carcinoma (UC) of the bladder is unclear. ...Our re …
Patient Characteristics, Treatment Patterns and Prognostic Factors in Squamous Cell Bladder Cancer.
Zahoor H, Elson P, Stephenson A, Haber GP, Kaouk J, Fergany A, Lee B, Koshkin V, Ornstein M, Gilligan T, Garcia JA, Rini B, Grivas P. Zahoor H, et al. Clin Genitourin Cancer. 2018 Apr;16(2):e437-e442. doi: 10.1016/j.clgc.2017.10.005. Epub 2017 Oct 17. Clin Genitourin Cancer. 2018. PMID: 29154041
BACKGROUND: Squamous cell carcinoma (SCC) is an uncommon histologic subtype of bladder cancer with limited data on treatment patterns, outcomes, and prognostic factors. ...Data on patient characteristics, treatment patterns, and clinical follow-up were …
BACKGROUND: Squamous cell carcinoma (SCC) is an uncommon histologic subtype of bladder cancer with limited data …
Squamous or Glandular Differentiation Predicts Poor Prognosis in pT1 Urothelial Carcinoma.
Nakagawa R, Iwamoto H, Makino T, Kadomoto S, Yaegashi H, Shigehara K, Izumi K, Kadono Y, Mizokami A. Nakagawa R, et al. In Vivo. 2022 Sep-Oct;36(5):2365-2370. doi: 10.21873/invivo.12968. In Vivo. 2022. PMID: 36099139 Free PMC article.
BACKGROUND: The aim of this study was to evaluate the prognosis of patients with T1N0M0 urothelial carcinoma with squamous differentiation (UCSD) or glandular differentiation (UCGD) because it has not been determined whether these variant histologies behave more agg …
BACKGROUND: The aim of this study was to evaluate the prognosis of patients with T1N0M0 urothelial carcinoma with squamous dif …
Expression and prognostic utility of PD-L1 in patients with squamous cell carcinoma of the bladder.
Owyong M, Lotan Y, Kapur P, Panwar V, McKenzie T, Lee TK, Zi X, Martin JW, Mosbah A, Abol-Enein H, Ghoneim M, Youssef RF. Owyong M, et al. Urol Oncol. 2019 Jul;37(7):478-484. doi: 10.1016/j.urolonc.2019.02.017. Epub 2019 Mar 23. Urol Oncol. 2019. PMID: 30910351
OBJECTIVES: Checkpoint inhibitors are approved for the treatment of urothelial bladder cancer. However, there have been no reports on the prognostic value of programmed-death receptor ligand 1 (PD-L1) expression in squamous cell carcinoma (SCC) of the …
OBJECTIVES: Checkpoint inhibitors are approved for the treatment of urothelial bladder cancer. However, there have been no reports on …
Oncologic Outcomes of Squamous Cell Carcinoma Versus Urothelial Carcinoma With Squamous Differentiation After Radical Cystectomy for Bladder Carcinoma.
Laymon M, Mosbah A, Hashem A, Mahmoud O, Harraz AM, Elsawy AA, Abol-Enein H. Laymon M, et al. Clin Genitourin Cancer. 2022 Apr;20(2):148-154. doi: 10.1016/j.clgc.2021.12.011. Epub 2021 Dec 16. Clin Genitourin Cancer. 2022. PMID: 34998698
INTRODUCTION: In this study we aim to compare clinicopathological characteristics and cancer specific survival between patients treated with radical cystectomy for pure squamous cell carcinoma (SCC) and urothelial carcinoma with squamous differe …
INTRODUCTION: In this study we aim to compare clinicopathological characteristics and cancer specific survival between patients treated with …
151 results